Core Insights - The article highlights the strategic initiatives of Hainan Xiansheng Pharmaceutical as it navigates the new phase of Hainan's full island closure, focusing on transforming policy benefits into health and industrial advancements [2][3]. Group 1: Company Strategy - Hainan Xiansheng Pharmaceutical has been operating for nearly thirty years and is actively implementing a "Lecheng research and application + Haikou production" model, which has successfully introduced the first domestically produced product of the global innovative drug "Kexaila" [2]. - The company is leveraging a series of innovative policies from Hainan's free trade port, including the Boao Lecheng pilot policy, which has reduced both research and development costs and time [2]. - The company has completed its first closed-loop transaction for processing and value-added domestic sales with zero tariffs, allowing for deeper integration of global resources and the establishment of a more competitive production base [2]. Group 2: Future Outlook - Hainan Xiansheng Pharmaceutical aims to enhance its hardware capabilities and achieve more domestic production of international innovative drugs, thereby supplying both domestic and global markets [3]. - The company expresses hope for more Hainan-based pharmaceutical companies and products to expand nationally and globally [4].
海南药企：将政策红利转化为健康福祉